CCL Aug 2015 - The Cancer Letter

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Request Cancellation

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

High-Risk Subset of CLL Patients Shows Benefit in Phase II Trial

ThermoDox plus RFA Increases Liver Cancer OS by 58 Percent in HEAT Study

Atezolizumab Immunotherapy Meets Response Endpoint in Phase II NSCLC Study

Oral Telotristat Etiprate Meets Primary Endpoint in Phase III Carcinoid Syndrome Trial

NCI CTEP-Approved Trials for the Month of August

European Commission Approves Unituxin In Pediatric High-Risk Neuroblastoma

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login